 Fibrosis is a disease characterized by excessive extracellular matrix deposition caused by fibroblast differentiation during inflammation, with limited treatment options due to unclear etiology. Long non-coding ironase, specifically H19, have emerged as potential therapeutic targets for fibrotic diseases due to their involvement in disease development and pathogenesis. This review summarizes recent advances in the mechanisms of H19 in fibrosis, highlighting its potential role as a promising target for treatment. This article was authored by Huan Li, Long Ting Cao, Honghui Liu, and others.